60,844 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 60,844 shares of the medical research company's stock, valued at approximately $15,858,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Swedbank AB grew its position in Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock worth $173,639,000 after acquiring an additional 5,751 shares in the last quarter. TrinityPoint Wealth LLC raised its stake in shares of Amgen by 0.8% during the third quarter. TrinityPoint Wealth LLC now owns 8,369 shares of the medical research company's stock valued at $2,696,000 after acquiring an additional 63 shares in the last quarter. Aljian Capital Management LLC raised its stake in Amgen by 398.1% in the third quarter. Aljian Capital Management LLC now owns 6,052 shares of the medical research company's stock worth $1,950,000 after buying an additional 4,837 shares in the last quarter. Phillips Financial Management LLC raised its stake in Amgen by 9.5% in the third quarter. Phillips Financial Management LLC now owns 705 shares of the medical research company's stock worth $227,000 after buying an additional 61 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in Amgen by 1,568.7% in the third quarter. Quest Partners LLC now owns 1,919 shares of the medical research company's stock worth $618,000 after purchasing an additional 1,804 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AMGN shares. Piper Sandler Companies reissued an "overweight" rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. UBS Group restated a "hold" rating on shares of Amgen in a research report on Wednesday, February 12th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $314.04.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded up $1.00 during trading on Friday, reaching $316.04. The stock had a trading volume of 9,994,350 shares, compared to its average volume of 2,552,453. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market capitalization of $169.78 billion, a price-to-earnings ratio of 41.86, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a fifty day simple moving average of $297.24 and a two-hundred day simple moving average of $299.02.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.01%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. The trade was a 12.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.